Results 271 to 280 of about 226,271 (312)
Some of the next articles are maybe not open access.
Raptor, a binding partner of target of rapamycin
Biochemical and Biophysical Research Communications, 2004The mammalian target of rapamycin (mTOR) controls cell growth in response to amino acids and growth factors, in part by regulating p70 S6 kinase alpha (p70 alpha) and eukaryotic initiation factor 4E binding protein 1 (4EBP1). Raptor (regulatory associated protein of mTOR) is a 150 kDa mTOR binding protein that is essential for TOR signaling in vivo and
Kazuyoshi, Yonezawa +3 more
openaire +2 more sources
Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine, 2018The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself ...
Z, Cai, Y, He, Y, Chen
openaire +2 more sources
Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia
Current Molecular Medicine, 2005Reflecting its critical role in integrating cell growth and division with the cellular nutritional environment, the mammalian target of rapamycin *(mTOR) is a highly conserved downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway. mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the
Francis J, Giles, Maher, Albitar
openaire +2 more sources
Mammalian target of rapamycin inhibitors in sarcomas
Current Opinion in Oncology, 2006Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its ...
openaire +2 more sources
Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors
Transplantation Reviews, 2008Mammalian target of rapamycin (mTOR) integrates nutrient and hormonal signals involved in cell growth. Development of mTOR inhibitor drugs as therapeutic agents for major human diseases such as obesity, diabetes, atherosclerosis, or cancer will experience an important increase in the next years. The incidence of these diseases is particularly increased
openaire +2 more sources
Clinical development of mammalian target of rapamycin inhibitors
Hematology/Oncology Clinics of North America, 2002Rapamycin and CCI-779 have significant in vitro and in vivo anti-proliferative activity against a broad range of human tumor cell lines, justifying the clinical evaluation of this class of agent in cancer patients. Preliminary results from phase I studies of CCI-779 suggest that the agent is well tolerated and has anti-tumor activity.
openaire +2 more sources
Mammalian Target of Rapamycin (mTOR)
2005The mammalian target of rapamycin (mTOR) is a giant serine/threonine protein kinase that plays a crucial role in a nutrient-sensitive signaling pathway that regulates cell growth and proliferation. The activity of mTOR is controlled by amino acids (especially by leucine, one of the branched-chain amino acids), in addition to growth factors and overall ...
openaire +1 more source